Röjdmark S, Edström E, Nordlund M
J Endocrinol Invest. 1984 Dec;7(6):635-9. doi: 10.1007/BF03349498.
To investigate whether chronic endogenous hypercalcemia influences TSH and/or PRL release from pituitary thyrotrophs and lactotrophs in man, 10 patients with endogenous hypercalcemia, due either to cancer or to primary hyperparathyroidism, were injected with 25 micrograms TRH iv. The TSH and PRL responses were compared with those obtained in an age-, sex-, and weight-matched group of patients comprised of 10 normocalcemic individuals with other diseases. The mean maximal TSH response in the hypercalcemic group (3.7 +/- 0.4 microU/ml) was 46% lower than in the normocalcemic group (6.8 +/- 1.2 microU/ml; p less than 0.02). Similarly, the mean maximal PRL response was 45% lower in the hypercalcemic (31 +/- 5 ng/ml) than in the normocalcemic patients (57 +/- 9 ng/ml; p less than 0.05). Feasible mechanisms behind this inhibitory influence of chronic endogenous hypercalcemia on TSH and PRL responsiveness are discussed.
为了研究慢性内源性高钙血症是否会影响人体垂体促甲状腺细胞和催乳细胞释放促甲状腺激素(TSH)和/或催乳素(PRL),对10例因癌症或原发性甲状旁腺功能亢进导致内源性高钙血症的患者静脉注射25微克促甲状腺激素释放激素(TRH)。将TSH和PRL的反应与由10名患有其他疾病的血钙正常个体组成的年龄、性别和体重匹配的患者组所获得的反应进行比较。高钙血症组的平均最大TSH反应(3.7±0.4微单位/毫升)比血钙正常组(6.8±1.2微单位/毫升;p<0.02)低46%。同样,高钙血症患者(31±5纳克/毫升)的平均最大PRL反应比血钙正常患者(57±9纳克/毫升;p<0.05)低45%。本文讨论了慢性内源性高钙血症对TSH和PRL反应性产生这种抑制作用背后的可能机制。